Avadel pharmaceuticals to present at the ladenburg thalmann annual healthcare conference 2021

Dublin, ireland, july 07, 2021 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that greg divis, chief executive officer of avadel, will participate in a fireside chat on wednesday, july 14 at 11:00 a.m. et.
AVDL Ratings Summary
AVDL Quant Ranking